IP Library Granted Patent US 8,476,050
Granted Patent B2
US 8,476,050 · App. 13/152,083 · Granted Jul 2, 2013

Conjugate preparation methods and related kit

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,050
App. No.
13/152,083
Granted
Jul 2, 2013
Kind
B2
Abstract

Methods for preparing conjugates including enzyme conjugates and especially alkaline phosphatase (ALP) conjugates, and a kit are provided. The methods include: blocking an amino group on a molecule surface of a first substance to be conjugated containing an amino group and a carboxyl group (for example, an enzyme) with a carboxyl compound; adding a carbodiimide to activate the first substance to be conjugated with the amino group blocked; inactivating or removing the carbodiimide; and adding a second substance containing an amino group (for example, a substance to be labeled). Conjugates (for example, enzyme conjugates) are obtained.

Claims (41)

1. A method for preparing a conjugate of a first substance to be conjugated and a second substance to be conjugated, the method comprising:

1) providing a first substance to be conjugated, wherein the first substance to be conjugated has a reactive amino group and a reactive carboxyl group and is an enzyme for labeling, selected from at least one of the following: alkaline phosphatase (ALP), horseradish peroxidase, β-galactosidase, urease, glucose-6-phosphate dehydrogenase, glucose oxidase, and malate dehydrogenase;

2) providing a second substance to be conjugated, wherein the second substance to be conjugated has a reactive amino group;

3) reacting a reactive amino group of the first substance to be conjugated with an amino group blocking agent that is a carboxyl compound having General Formula I, in the presence of a first cross-linking agent, to obtain a first substance to be conjugated having a blocked amino group:

wherein R 1 is selected from at least one of following: H, C 1-6 alkyl, C n H 2n COOH, phenyl, and phenylC 1-6 alkyl, wherein n is an integer of 0-4, and phenyl or phenylC 1-6 alkyl is optionally and independently substituted with a substitution group selected from at least one of the following: halogen, hydroxyl, mercapto, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, and carboxyl; and

R 2 is a group which is capable of dissociating in water; and wherein

the first cross-linking agent comprises a carbodiimide and, optionally, a hydroxysuccinimide;

4) optionally quenching the first cross-linking agent with a mercapto compound;

5) purifying the first substance to be conjugated having a blocked amino group;

6) reacting a second cross-linking agent with a reactive carboxyl group of the first substance to be conjugated having a blocked amino group, to create an activated first substance to be conjugated having a blocked amino group, wherein the second cross-linking agent comprises a carbodiimide and, optionally, a hydroxysuccinimide;

7) cross-linking the activated first substance to be conjugated having a blocked amino group, with a reactive amino group of the second substance to be conjugated to obtain a conjugate; and

8) optionally quenching the second cross-linking agent with a mercapto compound.

2. The method according to claim 1 , wherein the second substance to be conjugated is a peptide or a protein.

3. The method according to claim 2 , wherein the second substance to be conjugated is a targeting moiety selected from at least one of the following: an antibody and a ligand.

4. The method according to claim 1 , wherein the second substance to be conjugated is a hapten.

5. The method according to claim 1 , wherein the second substance to be conjugated is an amino group containing surface that is a solid phase.

6. The method according to claim 1 , wherein the second substance to be conjugated is a drug containing an amino group.

7. The method according to claim 1 , wherein the purification step comprises one or more of: ultrafiltration purification, desalting column purification, or dialysis purification.

8. The method according to claim 1 , wherein after activation of the carboxyl group of the first substance to be conjugated having a blocked amino group,

the activity of the second crosslinking agent is quenched by adding a mercapto compound, or

the second crosslinking agent is removed through purification,

yielding the first substance to be conjugated with the carboxyl group activated and having a blocked amino group.

9. The method according to claim 8 , wherein the mercapto compound is selected from at least one of the following: mercapto ethanol and mercapto threitol.

10. The method according to claim 8 , wherein the first substance to be conjugated with the carboxyl group activated and having a blocked amino group, is purified through one or more of ultrafiltration purification, desalting column purification, or dialysis purification.

11. The method according to claim 1 , wherein the carboxyl compound is selected from at least one of the following: formic acid, acetic acid, oxalic acid, benzoic acid, salicylic acid, and sulfosalicylic acid, or a salt thereof.

12. The method according to claim 1 , wherein the carbodiimide is selected from at least one of the following: dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N,N′-diisopropylcarbodiimide; and the hydroxysuccinimide is selected from at least one of the following: N-hydroxysucciniimde and sulfo-N-hydroxysuccinimide.

13. The method according to claim 1 , wherein in Step 3), the molar excess of the carboxyl compound is 500-200000 times that of the first substance to be conjugated.

14. The method according to claim 1 , wherein in Step 3), the molar excess of the cross-linking agent is 50-5000 times that of the first substance to be conjugated.

15. The method according to claim 1 , wherein in Step 3), the molar ratio of the carbodiimide to the hydroxysuccinimide is in a range of 5:1 to 1:10.

16. The method according to claim 1 , wherein in Step 6), the molar excess of the carbodiimide is 10-5000 times that of the first substance to be conjugated having a blocked amino group.

17. The method according to claim 1 , wherein in Step 6), the molar ratio of the carbodiimide to the hydroxysuccinimide is in a range of 5:1 to 1:10.

18. A kit for preparing a conjugate between an enzyme and a substance having a reactive amino group, or a substance to which a reactive amino group is introduced through modification, comprising:

1) an enzyme for labeling, selected from at least one of the following: alkaline phosphatase (ALP), horseradish peroxidase, β-galactosidase, urease, glucose-6-phosphate dehydrogenase, glucose oxidase, and malate dehydrogenase;

2) an amino group blocking agent for blocking reactive amino groups on the enzyme, said amino group blocking agent being a carboxyl compound having General Formula I:

where R 1 is selected from at least one of the following: H, C 1-6 alkyl, C n H 2n COOH, phenyl, and phenylC 1-6 alkyl, wherein n is an integer of 0-4, and phenyl or phenylC 1-6 alkyl is optionally and independently substituted with a substitution group selected from at least one of the following: halogen, hydroxyl, mercapto, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, and carboxyl; and R 2 is a group which is capable of dissociating in water;

3) a cross-linking agent, said cross-linking agent being a carbodiimide and, optionally, a hydroxysuccinimide; and

4) an optional cross-linking agent quenching agent, said quenching agent being a mercapto compound.

19. The kit according to claim 18 , wherein the carboxyl compound is selected from at least one of the following: formic acid, acetic acid, oxalic acid, benzoic acid, salicylic acid, and sulfosalicylic acid, or a salt thereof.

20. The kit according to claim 18 , wherein the carbodiimide is selected from at least one of the following: dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N,N′-diisopropylcarbodiimide; and the hydroxysuccinimide is selected from at least one of the following: N-hydroxysuccinimide and sulfo-N-hydroxysuccinimide.

21. The kit according to claim 18 , wherein the mercapto compound is selected from at least one of the following: mercapto ethanol and mercapto threitol.

22. The kit according to claim 18 , wherein the kit further comprises at least one of: an ultrafiltration tube, or instructions for operators.

Assignments (2)
LICENSE Recorded Jun 24, 2022
From: SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO., LTD.
To: SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.
Reel/Frame 060440/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2011
From: QIAN, CHUNGEN; LI, KE; ZHANG, YUPING
To: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
Reel/Frame 026380/0656 →